88 329

Cited 0 times in

Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.

Authors
 Sang Hyun Yoon  ;  Ki Hyang Kim  ;  Junjeong Choi  ;  Gun Min Kim  ;  Joo Hoon Kim  ;  Hyo Song Kim  ;  Young Nyun Park  ;  Sun Young Rha 
Citation
 Cancer Research and Treatment, Vol.42(3) : 180-184, 2010 
Journal Title
 Cancer Research and Treatment 
ISSN
 1598-2998 
Issue Date
2010
Abstract
The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.
Files in This Item:
T201004967.pdf Download
DOI
10.4143/crt.2010.42.3.180
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Kim, Gun Min(김건민) ORCID logo https://orcid.org/0000-0001-9167-8682
Kim, Ki Hyang(김기향)
Kim, Joo Hoon(김주훈)
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Park, Young Nyun(박영년) ORCID logo https://orcid.org/0000-0003-0357-7967
Yoon, Sang Hyun(윤상현)
Choi, Jun Jeong(최준정)
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/102869
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse